PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.50%
Revenue growth under 50% of MRVL's 9.11%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
4.89%
Gross profit growth under 50% of MRVL's 10.71%. Michael Burry would be concerned about a severe competitive disadvantage.
-10.62%
Negative EBIT growth while MRVL is at 19.85%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-10.62%
Negative operating income growth while MRVL is at 19.85%. Joel Greenblatt would press for urgent turnaround measures.
-12.81%
Negative net income growth while MRVL stands at 20.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-13.51%
Negative EPS growth while MRVL is at 21.43%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-9.09%
Negative diluted EPS growth while MRVL is at 7.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.65%
Share count expansion well above MRVL's 0.98%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.38%
Diluted share count expanding well above MRVL's 0.99%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
77.62%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
288.91%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
316.39%
10Y revenue/share CAGR at 50-75% of MRVL's 560.50%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
128.44%
5Y revenue/share CAGR under 50% of MRVL's 560.50%. Michael Burry would suspect a significant competitive gap or product weakness.
22.26%
3Y revenue/share CAGR under 50% of MRVL's 164.22%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
454.49%
10Y OCF/share CAGR under 50% of MRVL's 1109.00%. Michael Burry would worry about a persistent underperformance in cash creation.
269.07%
Below 50% of MRVL's 1109.00%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-16.91%
Negative 3Y OCF/share CAGR while MRVL stands at 484.85%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
326.17%
Below 50% of MRVL's 2805.34%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
80.39%
Below 50% of MRVL's 2805.34%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
220.98%
Below 50% of MRVL's 1121.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
849.40%
10Y equity/share CAGR at 75-90% of MRVL's 1032.42%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
189.67%
Below 50% of MRVL's 1032.42%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
38.39%
3Y equity/share CAGR above 1.5x MRVL's 19.99%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.03%
Firm’s AR is declining while MRVL shows 20.52%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-5.35%
Inventory is declining while MRVL stands at 31.30%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.47%
Asset growth at 75-90% of MRVL's 5.82%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
5.14%
BV/share growth above 1.5x MRVL's 3.01%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
2.47%
R&D dropping or stable vs. MRVL's 6.18%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
5.52%
SG&A growth well above MRVL's 3.54%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.